ReNetX Bio
New Haven, US · Delaware corporation
Biotech
Founders & leadership
ES
Erika SmithExecutive Officer, Director
GM
George MaynardExecutive Officer
DW
David WurzerDirector
GH
Gregory HoDirector
JP
John PuzissDirector
Reported raises · per SEC filings
Form D private placements▶$2.8MraisedSep 2020 · 6 investors · BiotechnologyRule 506(b)
▶$2.8MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory HoDirector
- Erika SmithExecutive Officer, Director
- John PuzissDirector
- George MaynardExecutive Officer
- David WurzerDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedJul 2019 · 6 investors · BiotechnologyRule 506(b)
▶$3.2MraisedJul 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David WurzerDirector
- John PuzissDirector
- Erika R. SmithExecutive Officer, Director
- Offering amount
- $3.2M
- Amount sold
- $3.2M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$425KraisedDec 2017 · 5 investors · BiotechnologyRule 506(b)
▶$425KraisedDec 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JOHN PUZISSDirector
- DAVID WURZERDirector
- ERIKA R. SMITHExecutive Officer, Director
- Offering amount
- $450K
- Amount sold
- $425K
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2013 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.